Comparison study of early radiotherapy combined with EP and EC therapy for limited-stage small cell lung cancer
MA Wenqing1 ZHANG Xuguang2 ZHAO Haiquan1 XU Yongmao1
1.Department of Radiotherapy, the 97th Hospital of People′s Liberation Army, Jiangsu Province, Xuzhou 221001, China;
2.Department of Radiotherapy, Xuzhou Cancer Hospital, Jiangsu Province, Xuzhou 221001, China
Abstract：Objective To explore the clinical effect and security on early radiotherapy combined with EP or EC therapy for limited-stage small cell lung cancer (LSCLC) and the influence on levels of the serum Ki-67 and VEGF. Methods A total of 70 cases with LSCLC in Department of Radiotherapy, the 97th Hospital of People′s Liberation Army from January 2013 to December 2014 were selected, and they were divided into EP group and EC group by the random number table method, with 35 cases in each group. The EP group was treated with VP-16 and DDP, while EC group was treated with and VP-16 and CBP. A treating course was 21 days, and both groups were treated for 6 courses. Concurrent radiotherapy was initiated after 2 courses of continuous chemotherapy. The clinical effect and adverse reactions were evaluated; the survival time was followed up. The levels of serum Ki-67 and VEGF before and after treatment were tested via ELISA. Results In EP group, the effective rate was 71.43%, and the disease control rate was 85.71%, while in EC group, they were 68.57%, 80.00% respectively, and there was no significant difference (P ＞ 0.05). In EP group, the overall survival time (OS) was 21.6 months, the 1-year survival rate was 74.29%, while in EC group, the OS was 22.1 months, the 1-year survival rate was 77.14%, and there was no significant difference (P ＞ 0.05). The adverse reactions rate of bone marrow suppression (neutrophile granulocyte, platelet decrease) was lower in EP group, while rate of gastrointestinal reaction, radiation pneumonitis, oesophagitis, abnormal liver function between the two groups had no significant difference (P ＞ 0.05). Compared with the levels of Ki-67, VEGF before treatment, the levels of Ki-67, VEGF decreased remarkably in the two groups after treatment, while more obvious in EC group(P ＜ 0.05). Conclusion There is no significant difference with the short-term effect in LSCLC between EP or EC therapy combined with early radiotherapy treatment, but EP therapy has fewer adverse reactions, with more obvious effect on suppressing the levels of serum Ki-67 and VEGF.
马文青1 张旭光2 赵海泉1 徐永茂1. 早期放疗联合EP和EC方案治疗局限期小细胞肺癌的临床对比研究[J]. 中国医药导报, 2018, 15(29): 96-99.
MA Wenqing1 ZHANG Xuguang2 ZHAO Haiquan1 XU Yongmao1. Comparison study of early radiotherapy combined with EP and EC therapy for limited-stage small cell lung cancer. 中国医药导报, 2018, 15(29): 96-99.
[1] Cai Q，Luo HL，Gao XC，et al. Clinical features and prognostic factors of small cell lung cancer：A retrospective study in 148 patients [J]. J Huazhong Univ Sci Technolog Med Sci，2016，36（6）：916-922.
[2] Kalemkerian GP，Schneider BJ. Advances in Small Cell Lung Cancer [J]. Hematol Oncol Clin North Am，2017，31（1）：143-156.
[3] 石远凯，孙燕，于金明，等.中国晚期原发性肺癌诊治专家共识（2016年版）[J].中国肺癌杂志2016，19（1）：1-14.
[4] 臧婉娜，苏景伟，祝淑钗，等.局限期小细胞肺癌不同局部治疗方式的比较研究[J].中华放射医学与防护杂志，2017，37（1）：40-43.
[5] Rami-Porta R，Bolejack V，Crowley J，et al. The IASLC Lung Cancer Staging Project：Proposals for the Revisions of the Descriptors in the Forthcoming Eighth Edition of the TNM Classfication for Lung Caner [J]. J Thorac Oncol，2015，10（7）：990-1003.
[6] Eisenhauer EA，Therasse P，Bogaerts J，et al. New response evaluation criteria in solid tumours：revised RECIST guideline （version 1.1）[J]. Eur J Cancer，2009，45（2）：228-247.
[7] 杨旭，许光，雷振，等.RECIST1.1与WHO、RECIST1.0标准评价周边型肺癌疗效比较[J].中国医学影像学杂志，2012，20（5）：255-258.
[8] Trotti A，Colevas AD，Setser A，et al. CTCAE v3.0：development of a comprehensive grading system for the adverse effects of cancer treatment [J]. Semin Radiat Oncol，2003， 13（3）：176-181.
[9] Koinis F，Kotsakis A，Georgoulias V. Small cell lung cancer（SCLC）：no treatment advances in recent years [J]. Transl Lung Cancer Res，2016，5（1）：39-50.
[10] Shi Y，Hu Y，Hu X，et al. Cisplatin combined with irinotecan or etoposide for untreated extensive stage small cell lung cancer：A multicenter randomized controlled clinical trial [J]. Thorac Cancer，2015，6（6）：785-791.
[11] Okamoto K，Okamoto I，Takeda M，et al. A phase I study of split-dose cisplatin and etoposide with concurrent accelerated hyperfractionated thoracic radiotherapy in elderly patients with limited-disease small cell lung cancer [J]. Jpn J Clin Oncol，2014，44（8）：743-748.
[12] Schmittel A，Sebastian M，Fischer L，et al. A German multicenter，randomized phase Ⅲ trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer [J]. Ann Oncol，2011，22（8）：1798-7804.
[13] Heger Z，Polanska H，Krizkova S，et al. Co-delivery of VP-16 and Bcl-2-targeted antisense on PEG-grafted oMWCNTs for synergistic in vitro anti-cancer effects in non-small and small cell lung cancer [J]. Colloids Surf B Biointerfaces，2017，150：131-140.
[14] Xu ZW，Mei J，Tan Y. Baicalin attenuates DDP（cisplatin）resistance in lung cancer by downregulating MARK2 and p-Akt [J]. Int J Oncol，2017，50（1）：93-100.
[15] Schluckebier L，Garay OU，Zukin M，et al. Carboplatin plus pemetrexed offers superior cost-effectiveness compared to pemetrexed in patients with advanced non-small cell lung cancer and performance status 2 [J]. Lung Cancer，2015，89（3）：274-279.
[16] Ito Y，Karayama M，Inui N，et al. Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy [J]. Lung Cancer，2014，84（3）：259-264.
[17] 陈华林，杨东红，李姝君，等.同步化放疗及序贯化放疗对局限期小细胞肺癌近期及远期效果的影响[J].广东医学，2017，38（8）：1222-1225.
[18] 苏景伟，祝淑钗，李娟，等.局限期小细胞肺癌局部放疗联合化疗预后影响因素分析[J].中华肿瘤防治杂志，2013， 20（16）：1257-1261.
[19] Yin H，Sheng Z，Zhang X，et al. Overexpression of SOX18 promotes prostate cancer progression via the regulation of TCF1，c-Myc，cyclin D1 and Ki-67 [J]. Oncol Rep，2017， 37（2）：1045-1051.
[20] 汪洁，刘斌，李莉，等.孤立性纤维性肿瘤影像学表现及与Ki-67表达的相关性[J].安徽医科大学学报，2017， 52（5）：777-789.
[21] 黄晓霞.血管内皮生长因子在小细胞肺癌中的表达及其与恶性程度相关性的研究[J].中国医药科学，2016，6（22）：166-168.
2018, Vol. 15 
京公网安备 11010502046598号